Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Q2 Revenues Inch up But Miss Analyst Estimates

NEW YORK (GenomeWeb News) – Waters today said that revenues for the second quarter inched up 1 percent, as the firm missed analyst estimates on the top line.

For the three months ended June 30, the firm posted revenues of $451.5 million, up just under 1 percent from $447.6 million for the second quarter of 2011, but missing Wall Street expectations of $458.4 million. Its organic growth for the quarter was 4 percent.

"H-Class Acquity LC and Xevo Tandem Quadropole systems, especially our ultra-sensitive Xevo TQS, continue to drive instrument systems growth," Waters Chairman, President, and CEO Douglas Berthiaume said on a conference call following the release of the results. "A combination of competitive pressure as well as the ASMS introduction of our new high performance Xevo QTOF G2-S, a system that will begin shipping in volume in the third quarter, resulted in a quarterly decline for high-end systems sales. We are encouraged by the ASMS customer reception and subsequent positive responses to recent demonstrations of our newly introduced Xevo QTOF G2-S and our Unify-based UPLC-MS/MS solutions."

However, Berthiaume also noted that "a big piece of that [high end mass spec] market is into non-profit government and academic labs. We're worried about that segment of the market more than others. We are beginning to ship our high end G2-S product, so we're hopeful that can stimulate things, but overall we're not holding out for a return to aggressive growth rates in that segment of the MS market."

Waters' profit for the quarter slid to $97.7 million, or $1.09 per share, from $100.1 million, or $1.07 per share, year over year. On a non-GAAP basis, EPS was $1.17, just above analyst estimates of $1.16.

"Operational efficiency allowed us to achieve our profitability objectives in light of challenging market conditions associated with a generally weaker global economic environment," Berthiaume noted in a statement.

The company recorded R&D expenses of $23.9 million, up 4 percent from $23.0 million a year ago, while SG&A expenses were down 2 percent to $122.7 million, from $125.4 million a year ago.

Waters finished the quarter with $1.39 billion in cash, cash equivalents, and short-term investments.

Waters officials said on the conference call that they expect the firm to report FY 2012 EPS of between $4.90 and $5.00 with organic revenue growth of 2 percent to 3 percent. Currency exchange is expected to lower its revenues by around 3 percent.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.